BioCentury | Mar 31, 2020
Deals

Lilly gains rights to Sitryx’s two most advanced immunometabolic programs in four-target deal

...to date. Eli Lilly and Co. (NYSE:LLY) gains exclusive, worldwide rights to four targets from Sitryx Therapeutics Ltd....
...outbreak. Targets IL17A - Interleukin-17A JAK-1 - Janus kinase-1 JAK-2 - Janus kinase-2 Paul Bonanos, Associate Editor Sitryx Therapeutics Ltd. Eli...
BioCentury | Nov 2, 2018
Targets & Mechanisms

Rethinking definitions of autoimmune disease

...solid tumors. This makes sense in autoimmunity, according to Paul-Peter Tak, co-founder of immuno-metabolism company Sitryx Therapeutics Ltd....
...Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. Scipher Medicine, Boston, Mass. Sitryx Therapeutics Ltd....
BioCentury | Oct 26, 2018
Product Development

R&D merry-go-round

...Tak, former chief immunology officer and SVP R&D pipeline at GSK. Tak is co-founder of Sitryx Therapeutics Ltd....
...of America (PhRMA), Washington, D.C. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Sanofi (NYSE:SNY; Euronext:SAN), Paris, France Sitryx Therapeutics Ltd....
BioCentury | Oct 12, 2018
Finance

Spinning out Sitryx

...With a $30 million series A round and a pipeline of immunometabolism programs, Sitryx Therapeutics Ltd. became the...
BioCentury | Oct 12, 2018
Financial News

Immunometabolism company Sitryx debuts with GSK ties, $30M

...Weir declined to disclose whether the series A round is tranched. Sitryx Therapeutics Ltd., Oxford, U.K. Allison Johnson GlaxoSmithKline plc Sitryx Therapeutics Ltd. SV...
BioCentury | Oct 8, 2018
Financial News

Immunometabolism company Sitryx debuts with GSK ties, $30M

...to disclose whether the series A round is tranched. Allison Johnson GlaxoSmithKline plc SV Health Investors Immunology Network immunometabolism Neil Weir Paul-Peter Tak Sitryx Therapeutics Ltd....
Items per page:
1 - 6 of 6
BioCentury | Mar 31, 2020
Deals

Lilly gains rights to Sitryx’s two most advanced immunometabolic programs in four-target deal

...to date. Eli Lilly and Co. (NYSE:LLY) gains exclusive, worldwide rights to four targets from Sitryx Therapeutics Ltd....
...outbreak. Targets IL17A - Interleukin-17A JAK-1 - Janus kinase-1 JAK-2 - Janus kinase-2 Paul Bonanos, Associate Editor Sitryx Therapeutics Ltd. Eli...
BioCentury | Nov 2, 2018
Targets & Mechanisms

Rethinking definitions of autoimmune disease

...solid tumors. This makes sense in autoimmunity, according to Paul-Peter Tak, co-founder of immuno-metabolism company Sitryx Therapeutics Ltd....
...Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. Scipher Medicine, Boston, Mass. Sitryx Therapeutics Ltd....
BioCentury | Oct 26, 2018
Product Development

R&D merry-go-round

...Tak, former chief immunology officer and SVP R&D pipeline at GSK. Tak is co-founder of Sitryx Therapeutics Ltd....
...of America (PhRMA), Washington, D.C. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Sanofi (NYSE:SNY; Euronext:SAN), Paris, France Sitryx Therapeutics Ltd....
BioCentury | Oct 12, 2018
Finance

Spinning out Sitryx

...With a $30 million series A round and a pipeline of immunometabolism programs, Sitryx Therapeutics Ltd. became the...
BioCentury | Oct 12, 2018
Financial News

Immunometabolism company Sitryx debuts with GSK ties, $30M

...Weir declined to disclose whether the series A round is tranched. Sitryx Therapeutics Ltd., Oxford, U.K. Allison Johnson GlaxoSmithKline plc Sitryx Therapeutics Ltd. SV...
BioCentury | Oct 8, 2018
Financial News

Immunometabolism company Sitryx debuts with GSK ties, $30M

...to disclose whether the series A round is tranched. Allison Johnson GlaxoSmithKline plc SV Health Investors Immunology Network immunometabolism Neil Weir Paul-Peter Tak Sitryx Therapeutics Ltd....
Items per page:
1 - 6 of 6